Use of the KADIS-CSII program for adjusting insulin pump therapy in type 1 diabetes

Show simple item record Vogt, L. Kohnert, K.D. Heinke, P. Thomas, A. Salzsieder, E. 2017-02-21T10:55:12Z 2017-02-21T10:55:12Z 2016-12-30
dc.identifier.citation Vogt, L. Use of the KADIS-CSII program for adjusting insulin pump therapy in type 1 diabetes/L. Vogt, K.-D. Kohnert, P. Heinke a.e.//Қарағанды ун-тінің хабаршысы. Биология.Медицина.География сер=Вестник Караганд.ун-та=Bulletin of the Karaganda university.-2016-№4(84).-P.25-33
dc.identifier.issn 2518-7201
dc.description.abstract Continuous subcutaneous insulin infusion (CSII) has become a standard for treatment optimization of type 1 diabetes (T1D). However, the transition from Multiple Dose Injection (MDI) to CSII therapy can be challenging. The objective of the present study was to use KADIS, the Karlsburg Diabetes Management System, for individual basal and bolus insulin adjustments in patients with type 1 diabetes while switching from MDI to pump therapy. We describe the extended KADIS-CSII program and its practical application for adjustment of insulin pump therapy. We conducted a pilot study including 12 patients with T1D who had received MDI therapy consisting of short- and long-acting insulin injections. Baseline HbA1c was 8.2±0.8 %, age 31.3±11.1 years, and diabetes duration 15.7±6.7 years (mean±SD). Data derived from continuous glucose monitoring (CGM) during MDI therapy were processed by the KADIS algorithm in order to characterise the patient’s specific metabolic parameters. Those were used to estimate individual basal infusion rate patterns as well as insulin boluses based on carbohydrate consumption for the transition to CSII. Three months after transitioning from MDI to CSII based on KADIS guided therapy, the mean HbA1c value was reduced to 7.6±0.5 % (–0.6 % vs. baseline, p<0.05) and remained at this level until the end of the 6-month study. Likewise, time <3.9 mmol/L (p=0.008), glycemic variability indexes, such as SD around mean glucose (p=0.010), MAGE (p=0.001), and CONGA (p=0.007), were all significantly lower at study end. Consistent with these data, quality of glycemia measured by the GRADE index and a recently developed Q-score was also improved. The proposed KADIS-CSII program could become a practicable and efficient tool to support adjusting insulin pump therapy. ru_RU
dc.language.iso en ru_RU
dc.publisher Вестник Карагандинского университета ru_RU
dc.relation.ispartofseries Биология;
dc.subject diabetes ru_RU
dc.subject insulin pump therapy ru_RU
dc.subject KADIS-program therapy ru_RU
dc.subject glycemia ru_RU
dc.subject glucose metabolism ru_RU
dc.subject HbA1 ru_RU
dc.title Use of the KADIS-CSII program for adjusting insulin pump therapy in type 1 diabetes ru_RU
dc.type Article ru_RU

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account